Related Experiment Video
Updated: Jan 27, 2026
A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic
Marie Bayer Elming1,2, Sophia Hammer-Hansen1, Inga Voges3,4
1Department of Cardiology, Rigshospitalet (M.B.E., S.H.-H., A.A.R., J.H.S., S.P., L.V.K., J.J.T.), University of Copenhagen, Denmark.
Insights
Right ventricular ejection fraction (RVEF) can predict survival benefits from implantable cardioverter-defibrillators (ICDs) in nonischemic systolic heart failure. Patients with RV systolic dysfunction showed improved outcomes with ICDs, highlighting RVEF
Area of Science:
- Cardiology
- Heart Failure Research
- Medical Imaging
Background:
- Nonischemic systolic heart failure (HF) patients face increased sudden cardiac death risk.
- Current tools lack precision in identifying HF patients who benefit from implantable cardioverter-defibrillators (ICDs).
- The role of right ventricular ejection fraction (RVEF) in guiding ICD therapy for nonischemic HF remains unclear.
Purpose of the Study:
- To investigate whether RVEF can identify patients with nonischemic systolic heart failure who are more likely to benefit from ICD implantation.
- To assess the association between RVEF, RV systolic dysfunction, and mortality outcomes in patients with nonischemic systolic heart failure.
Main Methods:
- Post hoc analysis of the DANISH trial, including patients with nonischemic systolic heart failure.
- Cardiovascular magnetic resonance (CMR) imaging to assess RVEF.
- Cox regression analysis to evaluate the impact of RVEF and ICDs on mortality.
Main Results:
- Right ventricular (RV) systolic dysfunction (RVEF ≤45%) was present in 31% of patients.
- Lower RVEF independently predicted all-cause mortality.
- ICD implantation significantly reduced all-cause mortality in patients with RV systolic dysfunction (HR 0.41) but not in those without (HR 1.87).
Conclusions:
- ICD therapy demonstrated a survival benefit in nonischemic systolic heart failure patients with biventricular dysfunction.
- RVEF is a significant predictor of mortality and may help stratify patients for ICD therapy.
- Prospective studies are needed to confirm these findings regarding RVEF and ICD efficacy.
Abstract:
Background Patients with nonischemic systolic heart failure are at an increased risk of sudden cardiac death, but more discriminating tools are needed to identify those patients likely to benefit from implantable cardioverter-defibrillator (ICD) implantation. Whether right ventricular (RV) ejection fraction (RVEF) can identify patients with nonischemic systolic heart failure more likely to benefit from ICD implantation is not yet known. Methods In this post hoc analysis of the DANISH trial (Danish Study to Assess the Efficacy of ICDs in Patients with Nonischemic Systolic Heart Failure on Mortality), patients with nonischemic systolic heart failure randomized to ICD or control underwent cardiovascular magnetic resonance. RV systolic dysfunction was defined as RVEF ≤45%. Cox regression assessed the effects of RV function and ICD implantation on all-cause mortality, sudden cardiac death, and cardiovascular death. Results Overall, 239 patients had interpretable images of RV volume. Median RVEF was 51%, RV systolic dysfunction was present in 75 (31%) patients, and 55 (23%) patients died. RVEF was an independent predictor of all-cause mortality, hazards ratio 1.34 per 10% absolute decrease in RVEF (95% CI, 1.05-1.70), P=0.02. There was a statistically significant interaction between RVEF and the effect of ICD implantation ( P=0.001). ICD implantation significantly reduced all-cause mortality in patients with RV systolic dysfunction, hazards ratio 0.41 (95% CI, 0.17-0.97), P=0.04 but not in patients without RV systolic dysfunction, hazards ratio 1.87 (95% CI, 0.85-3.92), P=0.12, ( P=0.01 for the difference in effect of ICD between RV groups). Conclusions In this post hoc analysis of the DANISH trial, ICD therapy was associated with survival benefit in patients with biventricular heart failure. These findings need confirmation in a prospective study. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00542945.
Related Concept Videos
01:17Pathophysiology of Heart Failure
01:27Heart Failure I: Introduction
01:29Heart Failure II: Pathophysiology
01:22Heart Failure Drugs: Diuretics
01:30Heart Failure V: Medical Management
01:22Heart Failure VI: Adjunct Therapies